Recon: FDA expected to authorize second COVID booster for 50 and older; UCB drug nabs FDA approval for Lennox-Gastaut Syndrome
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy